DB
AKYA

Dmitry Balyasny’s Akoya BioSciences AKYA Stock Holding History

Dmitry Balyasny’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-83,619
Closed -$1.62M – 1895
2021
Q2 		$1.62M Buy
+83,619
New +$1.73M 0.01% 1084

Other funds holding AKYA

BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
HEC
Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Dmitry Balyasny's AKYA Position: Q3 2021 in Review

Dmitry Balyasny sold out of Akoya BioSciences (AKYA) in Q3 2021, closing a stake of 83,619 shares — an estimated $1.62M sold.

Dmitry Balyasny first reported a position in AKYA in Q2 2021 and held it in 1 quarter. The position peaked at $1.62M in Q2 2021. 47 funds tracked by Wall St. Rank hold AKYA as of Q3 2021.

  • Dmitry Balyasny reported no remaining Akoya BioSciences position as of Q3 2021 after selling out during the quarter.
  • Dmitry Balyasny sold 83,619 Akoya BioSciences shares in Q3 2021, an estimated $1.62M.
  • Dmitry Balyasny first reported a position in Akoya BioSciences in Q2 2021 and held it in 1 quarter.
  • Dmitry Balyasny's Akoya BioSciences position peaked at $1.62M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.